SG11202008768VA - Pharmaceutical composition comprising brexpiprazole - Google Patents
Pharmaceutical composition comprising brexpiprazoleInfo
- Publication number
- SG11202008768VA SG11202008768VA SG11202008768VA SG11202008768VA SG11202008768VA SG 11202008768V A SG11202008768V A SG 11202008768VA SG 11202008768V A SG11202008768V A SG 11202008768VA SG 11202008768V A SG11202008768V A SG 11202008768VA SG 11202008768V A SG11202008768V A SG 11202008768VA
- Authority
- SG
- Singapore
- Prior art keywords
- brexpiprazole
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18461541.7A EP3545950A1 (en) | 2018-03-26 | 2018-03-26 | Pharmaceutical composition comprising brexpiprazole |
| PCT/EP2019/057016 WO2019185432A1 (en) | 2018-03-26 | 2019-03-21 | Pharmaceutical composition comprising brexpiprazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202008768VA true SG11202008768VA (en) | 2020-10-29 |
Family
ID=61768247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202008768VA SG11202008768VA (en) | 2018-03-26 | 2019-03-21 | Pharmaceutical composition comprising brexpiprazole |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP3545950A1 (en) |
| KR (1) | KR20200136399A (en) |
| AU (1) | AU2019245827B2 (en) |
| BR (1) | BR112020019410A2 (en) |
| CA (1) | CA3092948A1 (en) |
| CO (1) | CO2020012962A2 (en) |
| EA (1) | EA202092062A1 (en) |
| MX (1) | MX2020010113A (en) |
| PH (1) | PH12020551434A1 (en) |
| SG (1) | SG11202008768VA (en) |
| UA (1) | UA126702C2 (en) |
| WO (1) | WO2019185432A1 (en) |
| ZA (1) | ZA202006541B (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JP6034377B2 (en) * | 2011-06-27 | 2016-11-30 | シャンハイ チョンシ ファーマシューティカル コーポレイション | Aripiprazole pharmaceutical preparation and preparation method thereof |
| JO3753B1 (en) | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
| TW201332572A (en) | 2011-12-28 | 2013-08-16 | Otsuka Pharma Co Ltd | Pharmaceutical preparation comprising substituted β -cyclodextrin |
| CN105412036A (en) * | 2015-12-24 | 2016-03-23 | 北京康立生医药技术开发有限公司 | Brexpiprazole orally disintegrating tablets |
-
2018
- 2018-03-26 EP EP18461541.7A patent/EP3545950A1/en not_active Withdrawn
-
2019
- 2019-03-21 WO PCT/EP2019/057016 patent/WO2019185432A1/en unknown
- 2019-03-21 EA EA202092062A patent/EA202092062A1/en unknown
- 2019-03-21 EP EP19713738.3A patent/EP3773508A1/en active Pending
- 2019-03-21 CA CA3092948A patent/CA3092948A1/en active Pending
- 2019-03-21 BR BR112020019410-7A patent/BR112020019410A2/en unknown
- 2019-03-21 MX MX2020010113A patent/MX2020010113A/en unknown
- 2019-03-21 KR KR1020207027317A patent/KR20200136399A/en active Search and Examination
- 2019-03-21 UA UAA202006316A patent/UA126702C2/en unknown
- 2019-03-21 AU AU2019245827A patent/AU2019245827B2/en active Active
- 2019-03-21 SG SG11202008768VA patent/SG11202008768VA/en unknown
-
2020
- 2020-09-10 PH PH12020551434A patent/PH12020551434A1/en unknown
- 2020-10-16 CO CONC2020/0012962A patent/CO2020012962A2/en unknown
- 2020-10-21 ZA ZA2020/06541A patent/ZA202006541B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019185432A1 (en) | 2019-10-03 |
| BR112020019410A2 (en) | 2021-01-05 |
| AU2019245827B2 (en) | 2024-05-02 |
| EP3773508A1 (en) | 2021-02-17 |
| MX2020010113A (en) | 2020-11-06 |
| CO2020012962A2 (en) | 2020-10-30 |
| CA3092948A1 (en) | 2019-10-03 |
| PH12020551434A1 (en) | 2021-09-01 |
| KR20200136399A (en) | 2020-12-07 |
| ZA202006541B (en) | 2021-09-29 |
| AU2019245827A1 (en) | 2020-09-24 |
| EP3545950A1 (en) | 2019-10-02 |
| EA202092062A1 (en) | 2020-11-03 |
| UA126702C2 (en) | 2023-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271657A (en) | Pharmaceutical compositions | |
| IL269061A (en) | Pharmaceutical composition comprising selexipag | |
| IL271986B1 (en) | Pharmaceutical composition | |
| IL271759A (en) | Pharmaceutical compositions comprising entrectinib | |
| GB201712159D0 (en) | Pharmaceutical composition | |
| GB201804548D0 (en) | Pharmaceutical compositions | |
| GB201705303D0 (en) | Pharmaceutical compositions | |
| GB201911517D0 (en) | Pharmaceutical composition | |
| GB201713660D0 (en) | Pharmaceutical compositions | |
| GB201719447D0 (en) | Pharmaceutical composition | |
| IL272419A (en) | Pharmaceutical composition | |
| GB201705305D0 (en) | Pharmaceutical compositions | |
| GB201807053D0 (en) | Pharmaceutical composition | |
| SG11202103374TA (en) | Pharmaceutical composition | |
| GB201705304D0 (en) | Pharmaceutical compositions | |
| GB201705306D0 (en) | Pharmaceutical compositions | |
| EP3727485C0 (en) | Pharmaceutical composition | |
| GB201808571D0 (en) | Pharmaceutical compositions | |
| SG11202110315SA (en) | Pharmaceutical composition | |
| FI3908321T3 (en) | Pharmaceutical composition | |
| IL271513A (en) | Novel pharmaceutical composition | |
| IL272044A (en) | Pharmaceutical compositions | |
| GB201808567D0 (en) | Pharmaceutical compositions | |
| ZA202006541B (en) | Pharmaceutical composition comprising brexpiprazole | |
| GB201820689D0 (en) | Pharmaceutical composition |